What are the recent trends in market size and growth for the promacta market?
The promacta market size has grown strongly in recent years. It will grow from $3.79 billion in 2024 to $4.12 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to the increasing prevalence of immune thrombocytopenic purpura (ITP), a decrease in platelet counts, a growing incidence of illnesses including aplastic anemia and immune thrombocytopenia, a growing movement to enhance patient education, and a rise in healthcare expenditure.
The promacta market size is expected to see strong growth in the next few years. It will grow to $5.69 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to an increase in research and development, growing governmental efforts, an increasing global geriatric population, a growing movement to enhance patient education, an emphasis on patient assistance programs, growing healthcare infrastructure, and disposable incomes. Major trends in the forecast period include the creation of generic alternatives and biosimilars, a growing focus on patient-centric care, advancements in biotechnology and pharmaceuticals, the adoption of telemedicine and remote monitoring, and ongoing clinical trials and research initiatives.
Get Your Free Sample of The Global Promacta Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21264&type=smp
How have varous drivers impacted the growth of the promacta market?
The increasing prevalence of aplastic anemia is expected to propel the growth of the promacta market going forward. Aplastic anemia is a rare disorder in which the bone marrow fails to generate sufficient blood cells, causing fatigue, infections, and an increased risk of bleeding. The prevalence of aplastic anemia is due to exposure to toxic chemicals, certain medications, viral infections, autoimmune disorders, and genetic predisposition. Promacta stimulates bone marrow stem cells to produce blood cells, increasing counts of platelets, red blood cells, and neutrophils. It reduces the need for transfusions and decreases the risk of bleeding and infections in patients with aplastic anemia. For instance, in April 2024, according to the Anthony Nolan, a UK-based charity that works in leukemia and hematopoietic stem cell transplantation, approximately 100 to 150 people diagnosed with aplastic anemia in the UK annually. Therefore, the increasing prevalence of aplastic anemia is driving the growth of the promacta market.
Rise In Healthcare Expenditure Driving The Market Growth
The rise in healthcare expenditure is expected to propel the growth of the promacta market going forward. Healthcare expenditure is the overall cost of medical services, treatments, and infrastructure to preserve and enhance public and individual health. The rise in healthcare expenditure is driven by factors such as an aging population, advancements in medical technology, and increased health insurance coverage. The rise in healthcare expenditure enhances patient access to advanced treatments for thrombocytopenia and other blood disorders. It also improves diagnostic capabilities, facilitating early detection and increased adoption of PROMACTA. For instance, in December 2023, according to the Centers for Medicare & Medicaid Services, a US-based federal agency, U.S. healthcare spending increased by 4.1% in 2022, reaching $4.5 trillion, a faster growth rate than the 3.2% rise in 2021. Therefore, the rise in healthcare expenditure is driving the growth of the promacta market.
Increasing Geriatric Population Driving The Market Growth
The increasing geriatric population is expected to propel the growth of the promacta market going forward. The geriatric population comprises individuals aged 65 and above, often needing specialized care and support for age-related health concerns. The increasing geriatric population is due to rising life expectancy, improved healthcare, declining birth rates, and advancements in medical treatments. Promacta supports the geriatric population by boosting platelet production in blood disorders, reducing bleeding risks, strengthening immune function, and improving treatment outcomes, especially in older adults prone to platelet deficiencies. For instance, in January 2024, according to the Population Reference Bureau, a Kenya-based nonprofit organization, the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050. Therefore, the increasing geriatric population is driving the growth of the promacta market.
What are the primary segments of the promacta market?
The promacta market covered in this report is segmented –
1) By Indication: Chronic Immune Thrombocytopenia, Severe Aplastic Anemia, Hepatitis C-associated Thrombocytopenia, Other Indications
2) By Dosage Form: Tablets, Oral Suspension
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Chronic Immune Thrombocytopenia (ITP): Primary Immune Thrombocytopenia, Secondary Immune Thrombocytopenia
2) By Severe Aplastic Anemia: Adult Severe Aplastic Anemia, Pediatric Severe Aplastic Anemia
3) By Hepatitis C-associated Thrombocytopenia: Genotype 1 Hepatitis C-associated Thrombocytopenia, Genotype 2 Hepatitis C-associated Thrombocytopenia, Genotype 3 Hepatitis C-associated Thrombocytopenia
4) By Other Indications: Myelodysplastic Syndromes (MDS), Bone Marrow Disorders, Radiation-Induced Thrombocytopenia
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/promacta-global-market-report
Which firms are leading the promacta market?
Major companies operating in the promacta market are Novartis AG
Which geographic trends are shaping the promacta market, and which region has the highest market share?
North America was the largest region in the promacta market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the promacta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Promacta Market Report 2025 Offer?
The promacta market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Promacta (eltrombopag) is an oral thrombopoietin receptor agonist (TPO-RA) used to increase platelet production in patients with certain blood disorders. It is primarily prescribed for conditions where the body does not produce enough platelets, increasing the risk of bleeding. Promacta helps reduce the risk of bleeding in patients with low platelet counts.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21264
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
